Stelios Papadopoulos

Sep 04, 2008

Premium

Regulus Therapeutics, the microRNA joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week announced that it has appointed Stelios Papadopoulos to its board of directors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

NIH Boost Proposed

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Police, Genealogy, and Privacy

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

Gotta Sequence 'Em All

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

This Week in Science

In Science this week: environmental DNA can help in studies of marine animals, and more.

Featured White Papers

What to Look for in an Informatics Platform for Biologics R&D

The Ultimate Guide to Mouse Clinical Trials

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

How to Perform Successful CRISPR Experiments

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Main menu